Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

694

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Essential Hypertension
Interventions
DRUG

olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary

Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.

Trial Locations (79)

1080

Brussels

1196

Gland

1213

Petit Lancy

2800

Mechelen

4100

Centre Hospitalier du Bois de l'Abbaye et de Hesba, Department of Intensive Care, Seraing

5020

Salzburg

5026

Diakonissen-Krankenhaus Hospital, Salzburg-Aigen

6020

University Klinik, F. Innere Medizin, Innsbruck

Innsbruck

6166

Fulpmes

6250

Kundl

6500

Bellinzona

8050

Praxis Dreispitz, Zurich

8910

Zentrum Oberdorf, Affoltern am Albis

9140

Allgemeen Ziekenhuis Maria-Middelares, Cardiologie, Campus de Pelikaan, Temse

18000

Bourges

20142

Ospedale San Paolo, Milan

20148

Hamburg

20153

Ospedale San Carlo Borromeo, Milan

21320

Pouilly-en-Auxois

28844

Weyhe

30026

Presidio Ospedaliero di Portogruaro, Portogruaro (VE)

33100

Azienda Policlinico Universitario a Gestione Diret, Udine

33617

Ev. Krankenhaus Bielefeld, Medizinische Klinik in Bethel - Gilead I, Bielefeld

34560

Poussan

38100

Grenoble

44110

Saint-Aubin-des-Châteaux

44360

Saint-Étienne-de-Montluc

44590

Derval

47574

Goch

53111

Uniklinik Bonn, Bonn

55170

Ancerville

55190

Sorcy-Saint-Martin

58802

Balve

59037

Lille

63100

Ospedale C.G. Mazzoni, Ascoli Piceno

66013

"Università degli Studi G. D'Annunzio", Chieti Scalo

67000

Strasbourg

69115

Heidelberg

69120

Heidelberg (Neuenheim)

69245

Bammental

69800

Saint-Priest

70124

"Casa di Cura La Madonnina", Bari

75100

"Azienda Ospedaliera Madonna delle Grazie", Matera

76855

Annweiler am Trifels

78050

VS-Villingen

78054

Schwenningen

81100

Ospedale San Sebastiano, Caserta

83527

Haag

84453

Mühldorf / Inn

90146

Presidio Ospedaliero San Lorenzo, Palermo

91330

Yerres

95124

Ospedale Vittorio Emanuele, Catania

98051

Ospedale Nuovo Cutroni, Barcellona Pozzo Di Gotto (ME)

01340

Montrevel-en-Bresse

00041

Ospedale Regina Apostolorum, Albano Laziale (RM)

5216 GC

's-Hertogenbosch

5631 BM

Maxima Medisch Centrum, Eindhoven

7350-954

H. Elvas, Elvas

1214 JR

Hilversum

5737 CB

Lieshout

5144 CB

Waalwijk

2801-951

H. Almada, Almada Almada

2720-276

Hospital Fernando da Fonseca, Amadora Amadora

1169-024

Hospital de. S. Marta, Lisboa Lisboa

CV9 1EU

The Atherstone Surgery, Atherstone

B37 7TR

The Medical Centre, Birmingham

FY4 3AD

Waterloo Medical Centre, Blackpool

SN15 2SB

Rowden Surgery, Chippenham

CV6 4DD

The Gables Medical Centre, Coventry

RH10 1LL

Bridge Medical Centre, Crawley

EX1 2QS

Homefield Surgery, Exeter

G20 7LR

Woodside Health Centre, Glasgow

G45 9 AW

Castle Milk Health Centre, Glasgow

M13 9NT

Division of Cardiovascular and Endocrine Sciences, Manchester

M13 9WL

University of Manchester, Manchester

PL5 3PY

Oakside Surgery, Plymouth

S5 7HD

Norwood Medical Centre, Sheffield

BA14 7EG

Lovemead Group Practice, Trowbridge

All Listed Sponsors
lead

Sankyo Pharma Gmbh

INDUSTRY

NCT00311155 - Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension | Biotech Hunter | Biotech Hunter